Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on KalVista Pharmaceuticals and keeping the price target at $37.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on the promising initial performance of KalVista Pharmaceuticals’ new product, Ekterly. Despite being commercially available for only a short period, Ekterly has already generated significant sales, surpassing some expectations. This early success is indicative of a strong market reception and suggests a potential for substantial market penetration by the end of FY26.
Moreover, Ekterly’s sales are expected to increase significantly during CY26 as more patients begin using the drug. The company has already made strides in securing access through medical exceptions, and the potential for parity access with other branded therapies could further boost sales. Additionally, the management’s ability to navigate step-edit requirements effectively and the activation of a significant number of healthcare providers are positive indicators for future growth. These factors collectively underpin Chatterjee’s Buy rating and the price target of $37.
According to TipRanks, Chatterjee is a 5-star analyst with an average return of 36.8% and a 77.50% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Theravance Biopharma, Opus Genetics, and KalVista Pharmaceuticals.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $36.00 price target.